Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer, HER2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT06843681
What this trial is testing

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

Who this might be right for
Breast Carcinoma in Situ
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 54
Not applicableStudy completedNCT07211451
What this trial is testing

Axillary Nodal Burden in HER2+ and TNBC

Who this might be right for
Breast Cancer
Gangnam Severance Hospital 1,571
Testing effectiveness (Phase 2)UnknownNCT04881929
What this trial is testing

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 30
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Not applicableEnded earlyNCT03970967
What this trial is testing

Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

Who this might be right for
Breast CarcinomaMetastatic Breast CancerInvasive Breast Cancer+1 more
Alpha Tau Medical LTD. 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06639672
What this trial is testing

Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer

Who this might be right for
HR+HER2- Breast Cancer
Lei Liu 60
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Large-scale testing (Phase 3)Ended earlyNCT02137837
What this trial is testing

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 37
Large-scale testing (Phase 3)Active Not RecruitingNCT03734029
What this trial is testing

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Who this might be right for
Breast Cancer
Daiichi Sankyo 557
Testing effectiveness (Phase 2)Study completedNCT02073487
What this trial is testing

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Who this might be right for
Breast Cancer
The Methodist Hospital Research Institute 32
Testing effectiveness (Phase 2)Looking for participantsNCT05575804
What this trial is testing

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Who this might be right for
Advanced/ Metastatic Her-2 Positive Breast Cancer
Fudan University 32
Early research (Phase 1)Ended earlyNCT00251433
What this trial is testing

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 53
Not applicableLooking for participantsNCT05573893
What this trial is testing

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Who this might be right for
Breast NeoplasmsBreast CancerNeoplasm Metastasis
AstraZeneca 800
Testing effectiveness (Phase 2)Study completedNCT02018458
What this trial is testing

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Who this might be right for
Breast Cancer
Baylor Research Institute 10
Testing effectiveness (Phase 2)Study completedNCT00811135
What this trial is testing

Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 88
Not applicableLooking for participantsNCT04517838
What this trial is testing

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2-Positive Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8+3 more
Mayo Clinic 230
Large-scale testing (Phase 3)Looking for participantsNCT06977893
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 194
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Testing effectiveness (Phase 2)UnknownNCT03147963
What this trial is testing

Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 90
Next Page